RhumbLine Advisers
NVCT icon

RhumbLine Advisers’s Nuvectis Pharma NVCT Stock Holding History

RhumbLine Advisers’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
17,271
+8,614
+100% +$96.4K ﹤0.01% 3042
2026
Q1 		$66.9K Buy
8,657
+224
+3% +$1.92K ﹤0.01% 3534
2025
Q4 		$63.7K Sell
8,433
-2,897
-26% -$18.9K ﹤0.01% 3591
2025
Q3 		$68.2K Sell
11,330
-1,348
-11% -$9.27K ﹤0.01% 3603
2025
Q2 		$94.7K Buy
+12,678
New +$115K ﹤0.01% 3547
2024
Q3 		– Sell
-1,871
Closed -$11.8K – 4288
2024
Q2 		$11.8K Sell
1,871
-5,631
-75% -$38.3K ﹤0.01% 3959
2024
Q1 		$61.5K Buy
7,502
+229
+3% +$1.95K ﹤0.01% 3578
2023
Q4 		$60.7K Hold
7,273
– – ﹤0.01% 3581
2023
Q3 		$93.7K Buy
7,273
+495
+7% +$7.17K ﹤0.01% 3485
2023
Q2 		$108K Buy
+6,778
New +$108K ﹤0.01% 3498

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

RhumbLine Advisers's NVCT Position: Q2 2026 in Review

RhumbLine Advisers increased its Nuvectis Pharma (NVCT) stake by 100% in Q2 2026, buying an estimated $96.4K and bringing the position to 17,271 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

RhumbLine Advisers first reported a position in NVCT in Q2 2023 and has held it in 10 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • RhumbLine Advisers held 17,271 shares of Nuvectis Pharma worth $318K as of Q2 2026.
  • RhumbLine Advisers bought 8,614 Nuvectis Pharma shares in Q2 2026, an estimated $96.4K.
  • Nuvectis Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3042 holding.
  • RhumbLine Advisers first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 10 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.